| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/14/2009 | US20090124652 Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate |
| 05/14/2009 | US20090124633 N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases |
| 05/14/2009 | US20090124631 Combination Therapy |
| 05/14/2009 | US20090124628 polo-like kinase inhibitors used as antiproliferative and antitumor agents |
| 05/14/2009 | US20090124621 Pyrazole derivatives as kinase inhibitors |
| 05/14/2009 | US20090124615 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer |
| 05/14/2009 | US20090124612 Fused heterocyclic derivatives and methods of use |
| 05/14/2009 | US20090124611 Pyrazolopyridine-1,4-Diamines and Analogs Thereof |
| 05/14/2009 | US20090124609 Fused heterocyclic derivatives and methods of use |
| 05/14/2009 | US20090124605 Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors |
| 05/14/2009 | US20090124595 Mapk/erk kinase inhibitors |
| 05/14/2009 | US20090124587 METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS |
| 05/14/2009 | US20090124569 Inhibition and treatment of prostate cancer metastasis |
| 05/14/2009 | US20090124564 Compositions and methods for regulating apoptosis |
| 05/14/2009 | US20090124562 Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent |
| 05/14/2009 | US20090124554 Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| 05/14/2009 | US20090124537 Screening method for bone morphogenetic mimetics |
| 05/14/2009 | US20090124536 Calcium phosphate/sulfate-based bone implant composition |
| 05/14/2009 | US20090123938 Contacting a candidate antagonist with a MCP-1 receptor polypeptide having an amino acid sequence at least 95% homologous to an extracellular domain of a specific sequence, and comparing the binding of MCP-1 to the receptor polypeptide; decreased binding indicates an antagonist |
| 05/14/2009 | US20090123567 1,2-Bis[(1,2)-benzisoselenazol-3(2H)-onyl]ethane; high anti-oxidative activity and low toxicity; in combination with other anticarcinogenic, anticoagulant, antiinflammatory agents ( cisplatin, adriamycin, taxol; aspirin; indometacin) |
| 05/14/2009 | US20090123558 Polarized Scorpion Venom Solution and a Method for Making Polarized Scorpion Venom Solution |
| 05/14/2009 | US20090123533 Compositions and methods for cancer diagnosis and therapy |
| 05/14/2009 | US20090123532 Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
| 05/14/2009 | US20090123530 Liposome Drug Delivery |
| 05/14/2009 | US20090123516 Drug delivery from implants using self-assembled monolayers-therapeutic sams |
| 05/14/2009 | US20090123484 Methods for Diagnosing and Treating Kidney Cancer |
| 05/14/2009 | US20090123480 Bivalent smac mimetics and the uses thereof |
| 05/14/2009 | US20090123478 Human antibody molecules for IL-13 |
| 05/14/2009 | US20090123466 Anti-cd40 monoclonal antibody |
| 05/14/2009 | US20090123463 Methods and compositions for inducing apoptosis |
| 05/14/2009 | US20090123462 Fgfr agonists |
| 05/14/2009 | US20090123461 Human podocalyxin alternative-spliced forms and uses thereof |
| 05/14/2009 | US20090123450 Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation |
| 05/14/2009 | US20090123443 Method for Treating Colon Cancer |
| 05/14/2009 | US20090123442 Expanded nk cells |
| 05/14/2009 | US20090123433 Compositions Comprising Human Embryonic Stem Cells and their Derivatives, Methods of Use, and Methods of Preparation |
| 05/14/2009 | US20090123427 Method of Treating a Malignancy in a Subject and a Pharmaceutical Composition for Use in Same |
| 05/14/2009 | US20090123426 Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same |
| 05/14/2009 | US20090123420 Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase |
| 05/14/2009 | US20090123419 Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| 05/14/2009 | US20090123417 Recombinant super-compound interferon and uses thereof |
| 05/14/2009 | US20090123416 Methods for the treatment of bladder cancer using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
| 05/14/2009 | US20090123388 Prodrugs of Short-Chain Fatty Acids and Treatment Methods |
| 05/14/2009 | US20090123382 Light emitting microorganisms and cells for diagnosis and therapy of tumors |
| 05/14/2009 | US20090123381 Imaging and therapeutic targeting of prostate and bladder tissues |
| 05/14/2009 | US20090123376 Therapeutic agents with decreased toxicity |
| 05/14/2009 | US20090123374 Methods for determining cancer resistance to histone deacetylase inhibitors |
| 05/14/2009 | US20090123371 Molecular signature of cancer |
| 05/14/2009 | US20090123370 Alphavbeta6 peptide ligands and their uses |
| 05/14/2009 | US20090123367 Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| 05/14/2009 | DE102007054411A1 Verwendung einer Ozon-/Sauerstoffmischung als primäre Antikrebstherapie durch intraperitoneale Insufflation Using a ozone / oxygen mixture as the primary anti-cancer therapy by intraperitoneal insufflation |
| 05/14/2009 | DE10163130B4 Apoptotisch wirksame Peptide und diese umfassende pharmazeutische Zusammensetzungen Apoptotic active peptides and pharmaceutical compositions comprising |
| 05/14/2009 | CA2705263A1 Uses of anti-cd40 antibodies |
| 05/14/2009 | CA2705152A1 Anti-vegf antibody compositions and methods |
| 05/14/2009 | CA2705092A1 Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| 05/14/2009 | CA2704648A1 Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| 05/14/2009 | CA2704583A1 Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
| 05/14/2009 | CA2704395A1 Combination therapy with organic arsenicals |
| 05/14/2009 | CA2704000A1 Combination of anti-angiogenic substance and anti-tumor platinum complex |
| 05/14/2009 | CA2703987A1 Cyclobutyl carboxylic acid derivatives |
| 05/14/2009 | CA2703792A1 Corticosteroids to treat epothilone or epothilone derivative induced diarrhea |
| 05/14/2009 | CA2703099A1 Activin receptor-like kinase-i compositions and methods of use |
| 05/14/2009 | CA2702995A1 Compounds for inhibiting ksp kinesin activity |
| 05/14/2009 | CA2702990A1 Compounds for inhibiting ksp kinesin activity |
| 05/14/2009 | CA2702985A1 Compounds for inhibiting ksp kinesin activity |
| 05/14/2009 | CA2696807A1 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
| 05/13/2009 | EP2058658A2 Method and means for influencing intercellular communication and intercellular organelle transport |
| 05/13/2009 | EP2058399A1 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 05/13/2009 | EP2058395A1 Kif-derived peptide capable of binding to hla-a24 molecule |
| 05/13/2009 | EP2058334A2 Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| 05/13/2009 | EP2058332A1 Use of CD25 binding molecules in steroid-resistant patients |
| 05/13/2009 | EP2058320A1 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 05/13/2009 | EP2058317A1 Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
| 05/13/2009 | EP2058314A1 Pyrrolotriazine compounds as kinase inhibitors |
| 05/13/2009 | EP2058312A1 SMAC mimetic compounds as apoptosis inducers |
| 05/13/2009 | EP2058307A1 Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases |
| 05/13/2009 | EP2058302A1 Method for producing phenoxypyridine derivative |
| 05/13/2009 | EP2058293A1 Lipoxin compounds and their use in treating cell proliferative disorders |
| 05/13/2009 | EP2057999A2 Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| 05/13/2009 | EP2057997A1 Preventive and/or therapeutic agent for peripheral neuropathy |
| 05/13/2009 | EP2057193A2 Ephb3-specific antibody and uses thereof |
| 05/13/2009 | EP2057165A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases |
| 05/13/2009 | EP2057164A1 Triazolotriazines as kinase inhibitors |
| 05/13/2009 | EP2057161A2 4-oxo-4,5-dihydropyrrolo[1,2-a]quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| 05/13/2009 | EP2057158A1 Triazole derivatives as kinase inhibitors |
| 05/13/2009 | EP2057157A2 2-amido-4-isoxazolyl thiazole compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 05/13/2009 | EP2057155A1 1h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitors |
| 05/13/2009 | EP2057147A1 Pyrimidine derivatives |
| 05/13/2009 | EP2057146A1 Compounds and compositions as protein kinase inhibitors |
| 05/13/2009 | EP2057144A2 Novel polymorphs of rimonabant |
| 05/13/2009 | EP2057143A2 5-substituted isoindoline compounds |
| 05/13/2009 | EP2057129A1 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| 05/13/2009 | EP2057118A2 Compounds for treatment of proliferative disorders |
| 05/13/2009 | EP2057117A2 Compounds for treating proliferative disorders |
| 05/13/2009 | EP2056886A2 68ga-labeled peptide-based radiopharmaceuticals |
| 05/13/2009 | EP2056868A1 Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein |
| 05/13/2009 | EP2056854A1 Method for reducing incidence or rate of development of skin cancers and related conditions |
| 05/13/2009 | EP2056845A2 Structure and use of 5' phosphate oligonucleotides |
| 05/13/2009 | EP2056839A1 Combination approaches to cancer treatment |
| 05/13/2009 | EP2056838A2 Combination therapy for treatment of immune disorders |